Market Place
Sourcing Support
Eyenovia Announces $1.9M Registered Direct Offering Pricing
06 Dec 2024 //
GLOBENEWSWIRE
Eyenovia Announces $1.3 Million Registered Direct Offering
25 Nov 2024 //
GLOBENEWSWIRE
Eyenovia Provides Update on Restructuring Efforts
22 Nov 2024 //
GLOBENEWSWIRE
Eyenovia to end eye drug study, cut 50% of its workforce
16 Nov 2024 //
REUTERS
Eyenovia Provides Update on Phase 3 CHAPERONE Study
15 Nov 2024 //
GLOBENEWSWIRE
Eyenovia Reports Q3 2024 Financial Results & Corporate Update
12 Nov 2024 //
GLOBENEWSWIRE
Eyenovia to Report Q3 2024 Results on Tuesday, November 12th
07 Nov 2024 //
GLOBENEWSWIRE
Eyenovia Publishes Study on Optejet®`s Ocular Impact
23 Oct 2024 //
GLOBENEWSWIRE
Eyenovia Presents Phase 3 Clobetasol Study Results At AAO Expo
16 Oct 2024 //
GLOBENEWSWIRE
Eyenovia Starts Manufacturing Second Generation Optejet Device
01 Oct 2024 //
GLOBENEWSWIRE
Eyenovia Announces Pricing Of $4 Million Registered Offering
27 Sep 2024 //
GLOBENEWSWIRE
Eyenovia Announces Launch Of Clobetasol Propionate Suspension
26 Sep 2024 //
GLOBENEWSWIRE
Eyenovia Announces Taiwan Export License Approval
05 Sep 2024 //
GLOBENEWSWIRE
Eyenovia Appoints Andrew Jones as Chief Financial Officer
03 Sep 2024 //
GLOBENEWSWIRE
Eyenovia Announces Closing of Public Offering
23 Aug 2024 //
GLOBENEWSWIRE
Eyenovia Announces Pricing of $5.14 Million Public Offering
21 Aug 2024 //
GLOBENEWSWIRE
Eyenovia, Inc. Announces Proposed Public Offering
20 Aug 2024 //
GLOBENEWSWIRE
Eyenovia To Participate In H.C. Wainwright Ophthalmology Conference
13 Aug 2024 //
GLOBENEWSWIRE
Eyenovia Reports Q2 2024 Results And Provides Corporate Update
12 Aug 2024 //
GLOBENEWSWIRE
Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th
08 Aug 2024 //
GLOBENEWSWIRE
Formosa Pharma And Eyenovia Initiate Co-Development Of Clobetasol Suspension
08 Aug 2024 //
PR NEWSWIRE
Processa Receives FDA IND Clearance For NGC-Cap Phase 2 Trial
30 Jul 2024 //
GLOBENEWSWIRE
Eyenovia And Senju Partner On New Chronic Dry Eye Disease Treatment
23 Jul 2024 //
GLOBENEWSWIRE
Eyenovia Announces Pricing of $5M Registered Direct Offering
28 Jun 2024 //
GLOBENEWSWIRE
Eyenovia Reports Q1 2024 Results, Myopia, Commercial Product Updates
15 May 2024 //
GLOBENEWSWIRE
Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th
14 May 2024 //
GLOBENEWSWIRE
Eyenovia Updates on Mydcombi„ & Clobetasol Ophthalmic Suspension
25 Apr 2024 //
GLOBENEWSWIRE
Eyenovia Announces Updated Strategy and Corporate Priorities
08 Apr 2024 //
GLOBENEWSWIRE
Eyenovia to Feature its Suite of Products and the Optejet Dispenser at Meetings
03 Apr 2024 //
GLOBENEWSWIRE
Eyenovia Reports Fourth Quarter & Full-Year 2023 Financial Results
18 Mar 2024 //
GLOBENEWSWIRE
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results
18 Mar 2024 //
GLOBENEWSWIRE
NovaBay and Eyenovia to Co-Promote Prescription Ophthalmic Products
13 Mar 2024 //
GLOBENEWSWIRE
Eyenovia to Report Fourth Quarter 2023 Results
11 Mar 2024 //
GLOBENEWSWIRE
US FDA approves Eyenovia`s eye drug, Formosa Pharma says
05 Mar 2024 //
REUTERS
Eyenovia Announces FDA Approval of Redwood City as Manufacturing Facility
13 Feb 2024 //
GLOBENEWSWIRE
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine
16 Jan 2024 //
GLOBENEWSWIRE
Eyenovia Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
06 Nov 2023 //
GLOBENEWSWIRE
Eyenovia Announces FDA Approval of Coastline International
02 Nov 2023 //
GLOBENEWSWIRE
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO™s 51st ACE
30 Oct 2023 //
GLOBENEWSWIRE
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet
09 Oct 2023 //
GLOBENEWSWIRE
Eyenovia to Participate in Discussion at Cantor Global Healthcare Conference
21 Sep 2023 //
GLOBENEWSWIRE
Eyenovia to Present at H.C. Wainwright 25th Annual Global Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Eyenovia Announces $12 Million Registered Direct Offering
24 Aug 2023 //
GLOBENEWSWIRE
Formosa Pharma inks $86 M worth ophthalmology deal with American firm Eyenovia
21 Aug 2023 //
BIOSPECTRUM ASIA
Formosa Announces Agreement with Eyenovia for the Commercialization of APP13007
16 Aug 2023 //
PR NEWSWIRE
Eyenovia Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Eyenovia to Present at H.C. Wainwright 3rd Annual Ophthalmology Conference
09 Aug 2023 //
GLOBENEWSWIRE
Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10
07 Aug 2023 //
GLOBENEWSWIRE
Eyenovia Announces First Commercial Sale of Mydcombi„¢
03 Aug 2023 //
GLOBENEWSWIRE
Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
26 Jun 2023 //
GLOBENEWSWIRE
Eyenovia Expands Its US Manufacturing Capabilities
06 Jun 2023 //
ACCESSWIRE
Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023
01 Jun 2023 //
GLOBENEWSWIRE
Eyenovia Reports First Quarter 2023 Financial Results & Provides Business Update
11 May 2023 //
GLOBENEWSWIRE
Eye tech company snags first-ever approval for spray to dilate pupils
09 May 2023 //
ENDPTS
US FDA approves Eyenovia`s pupil-dilating spray
09 May 2023 //
REUTERS
Eyenovia Announces FDA Approval of Mydcombi„¢, the First Ophthalmic Spray
08 May 2023 //
GLOBENEWSWIRE
Eyenovia to Report First Quarter 2023 Results on Thursday, May 11
04 May 2023 //
GLOBENEWSWIRE
Eyenovia Announces Poster Presentation at ARVO 2023
24 Apr 2023 //
GLOBENEWSWIRE
Eyenovia Reports 4Q Financial Results 2022Financial Results
30 Mar 2023 //
GLOBENEWSWIRE
